Cargando…
Macrophage-Based Therapies for Atherosclerosis Management
Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204102/ https://www.ncbi.nlm.nih.gov/pubmed/32411803 http://dx.doi.org/10.1155/2020/8131754 |
_version_ | 1783529993706405888 |
---|---|
author | Peng, Renyi Ji, Hao Jin, Libo Lin, Sue Huang, Yijiang Xu, Ke Yang, Qinsi Sun, Da Wu, Wei |
author_facet | Peng, Renyi Ji, Hao Jin, Libo Lin, Sue Huang, Yijiang Xu, Ke Yang, Qinsi Sun, Da Wu, Wei |
author_sort | Peng, Renyi |
collection | PubMed |
description | Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation. |
format | Online Article Text |
id | pubmed-7204102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-72041022020-05-14 Macrophage-Based Therapies for Atherosclerosis Management Peng, Renyi Ji, Hao Jin, Libo Lin, Sue Huang, Yijiang Xu, Ke Yang, Qinsi Sun, Da Wu, Wei J Immunol Res Review Article Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation. Hindawi 2020-01-29 /pmc/articles/PMC7204102/ /pubmed/32411803 http://dx.doi.org/10.1155/2020/8131754 Text en Copyright © 2020 Renyi Peng et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Peng, Renyi Ji, Hao Jin, Libo Lin, Sue Huang, Yijiang Xu, Ke Yang, Qinsi Sun, Da Wu, Wei Macrophage-Based Therapies for Atherosclerosis Management |
title | Macrophage-Based Therapies for Atherosclerosis Management |
title_full | Macrophage-Based Therapies for Atherosclerosis Management |
title_fullStr | Macrophage-Based Therapies for Atherosclerosis Management |
title_full_unstemmed | Macrophage-Based Therapies for Atherosclerosis Management |
title_short | Macrophage-Based Therapies for Atherosclerosis Management |
title_sort | macrophage-based therapies for atherosclerosis management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204102/ https://www.ncbi.nlm.nih.gov/pubmed/32411803 http://dx.doi.org/10.1155/2020/8131754 |
work_keys_str_mv | AT pengrenyi macrophagebasedtherapiesforatherosclerosismanagement AT jihao macrophagebasedtherapiesforatherosclerosismanagement AT jinlibo macrophagebasedtherapiesforatherosclerosismanagement AT linsue macrophagebasedtherapiesforatherosclerosismanagement AT huangyijiang macrophagebasedtherapiesforatherosclerosismanagement AT xuke macrophagebasedtherapiesforatherosclerosismanagement AT yangqinsi macrophagebasedtherapiesforatherosclerosismanagement AT sunda macrophagebasedtherapiesforatherosclerosismanagement AT wuwei macrophagebasedtherapiesforatherosclerosismanagement |